Axsome Therapeutics’ AXSM Auvelity (AXS-05) was launched in the United States in 2022 for the treatment of major depressive disorder (MDD), making it the first approved drug in the company’s portfolio ...

Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound suitable for clinical testing — a drug candidate. It is based on ...

Based on the FDA's feedback, Axsome plans to submit a supplemental NDA for AXS-05 in Alzheimer's disease agitation in third-quarter 2025.

There is no medication specifically for intrusive thoughts, but drugs that alleviate the underlying cause may also reduce the intrusive thoughts. Various conditions can cause intrusive thoughts ...

Doctors refer to hair loss that occurs as a side effect of medication as drug-induced alopecia. Hair loss can be a side effect of many different medications, such as those for chemotherapy.

Section 5A RTA 1988 - Driving or being in charge with concentration of specified controlled drug above specified limit The offence at section 5A RTA 1988 is driving, attempting to drive or being in ...

With a strong commercial foundation in AUVELITY and potential near-term catalysts from its pipeline, the company is well-positioned for growth. However, investors should remain cognizant of the risks ...

AUVELITY has demonstrated impressive uptake ... fourth quarter of 2024 and could potentially lead to a supplemental New Drug Application (sNDA) filing in the first half of 2025.

In 2020, Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now marketed as Leqembi. Four years later, she and her husband, Ken, halted the treatment.

The first line of pharmacological treatment for schizophrenia is antipsychotic medication. However, antipsychotic medications are ineffective in more than 30% of people with the disorder. This is ...

Auvelity treats major depressive disorder (MDD), and Sunosi is an oral medication for the treatment of excessive daytime sleepiness (EDS) in patients with narcolepsy or obstructive sleep apnea.

In jails and prisons, drugs are still available, effective treatment is rare, and overdoses occur. People can also cycle in and out of jail, ending up back on the street without meaningful care or ...